Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 97985-66-5 | MDL No. : | MFCD00996500 |
Formula : | C9H7BrO | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | QICJGJJHIQBWJR-DUXPYHPUSA-N |
M.W : | 211.06 | Pubchem ID : | 5823756 |
Synonyms : |
|
Num. heavy atoms : | 11 |
Num. arom. heavy atoms : | 6 |
Fraction Csp3 : | 0.0 |
Num. rotatable bonds : | 2 |
Num. H-bond acceptors : | 1.0 |
Num. H-bond donors : | 0.0 |
Molar Refractivity : | 49.24 |
TPSA : | 17.07 Ų |
GI absorption : | High |
BBB permeant : | Yes |
P-gp substrate : | No |
CYP1A2 inhibitor : | Yes |
CYP2C19 inhibitor : | No |
CYP2C9 inhibitor : | No |
CYP2D6 inhibitor : | No |
CYP3A4 inhibitor : | No |
Log Kp (skin permeation) : | -5.6 cm/s |
Log Po/w (iLOGP) : | 2.02 |
Log Po/w (XLOGP3) : | 2.8 |
Log Po/w (WLOGP) : | 2.55 |
Log Po/w (MLOGP) : | 2.73 |
Log Po/w (SILICOS-IT) : | 3.14 |
Consensus Log Po/w : | 2.65 |
Lipinski : | 0.0 |
Ghose : | None |
Veber : | 0.0 |
Egan : | 0.0 |
Muegge : | 1.0 |
Bioavailability Score : | 0.55 |
Log S (ESOL) : | -3.18 |
Solubility : | 0.138 mg/ml ; 0.000654 mol/l |
Class : | Soluble |
Log S (Ali) : | -2.82 |
Solubility : | 0.323 mg/ml ; 0.00153 mol/l |
Class : | Soluble |
Log S (SILICOS-IT) : | -3.29 |
Solubility : | 0.107 mg/ml ; 0.000508 mol/l |
Class : | Soluble |
PAINS : | 0.0 alert |
Brenk : | 2.0 alert |
Leadlikeness : | 1.0 |
Synthetic accessibility : | 2.0 |
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P280-P305+P351+P338 | UN#: | N/A |
Hazard Statements: | H302 | Packing Group: | N/A |
GHS Pictogram: |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
42.2 %Spectr. | With trifluoroacetic acid; sodium nitrite In chloroform at 0 - 20℃; | General procedure: Sodium nitrite, 0.69 g (0.01 mol), was added in portions over a period of 10–15 min to a mixture of 0.01 mol of arylcyclopropane 1a–1l, 5.2 g of trifluoroacetic acid, and 15 mL of chloroform, cooled to 0–5 °C.The mixture was allowed to warm up to 20 °C, kept for1 h at that temperature, and poured into 100 mL of cold water. The organic phase was separated, the aqueousphase was extracted with chloroform (2 × 10 mL), the extracts were combined with the organic phase,washed with water (2 × 30 mL), and dried over MgSO4, the solvent was removed, and the residue was analyzed by 1H NMR. Compound 2l was isolated by crystallization. The compositions of the reaction mixtures are given in Table 1. The physical constants and spectral characteristics of 2a [16], 2b [30], and 2l [28] coincided with published data. 5-(3-Bromophenyl)-4,5-dihydro-1,2-oxazole (2c). Viscous oily material. 1H NMR spectrum, δ, ppm:2.98 d.d.d (1H, 4-H, J = 2.0, 7.4, 17.8 Hz) and 3.46 d.d.d (1H, 4-H, J = 2.0, 10.5, 17.8 Hz), 5.51 d.d (1H, 5-H, J = 7.4, 10.5 Hz), 7.23 s (1H, 3-H), 7.23–7.28 m (3H, Harom), 7.49 m (1H, Harom). Found, percent:C 47.33, 47.51; H 3.36, 3.42; N 5.91, 6.02. C9H8BrNO. Calculated, percent: C 47.82; H 3.57; N 6.20. |
[ 49678-04-8 ]
(E)-3-(4-Bromophenyl)acrylaldehyde
Similarity: 0.97
[ 49678-04-8 ]
(E)-3-(4-Bromophenyl)acrylaldehyde
Similarity: 0.97
[ 138555-58-5 ]
(E)-3-(2-Bromophenyl)acrylaldehyde
Similarity: 0.86
[ 18869-30-2 ]
(E)-1,2-Bis(4-bromophenyl)ethene
Similarity: 0.81
[ 49678-04-8 ]
(E)-3-(4-Bromophenyl)acrylaldehyde
Similarity: 0.97
[ 49678-04-8 ]
(E)-3-(4-Bromophenyl)acrylaldehyde
Similarity: 0.97